NO315637B1 - Blanding i oral doseringsform inneholdende paroxetin eller et farmasöytiskakseptabelt salt derav, samt anvendelse av og fremgangsmåte forfremstilling avblandingen - Google Patents
Blanding i oral doseringsform inneholdende paroxetin eller et farmasöytiskakseptabelt salt derav, samt anvendelse av og fremgangsmåte forfremstilling avblandingen Download PDFInfo
- Publication number
- NO315637B1 NO315637B1 NO19980240A NO980240A NO315637B1 NO 315637 B1 NO315637 B1 NO 315637B1 NO 19980240 A NO19980240 A NO 19980240A NO 980240 A NO980240 A NO 980240A NO 315637 B1 NO315637 B1 NO 315637B1
- Authority
- NO
- Norway
- Prior art keywords
- mixture
- release
- controlled
- deposition core
- dosage form
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 36
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title claims description 23
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 title claims description 22
- 229960002296 paroxetine Drugs 0.000 title claims description 22
- 239000006186 oral dosage form Substances 0.000 title claims description 7
- 150000003839 salts Chemical class 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims 2
- 238000000034 method Methods 0.000 title description 9
- 239000013543 active substance Substances 0.000 claims description 15
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 13
- 238000013270 controlled release Methods 0.000 claims description 12
- 230000008021 deposition Effects 0.000 claims description 12
- 230000003111 delayed effect Effects 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 8
- 229920000642 polymer Polymers 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 4
- 229940095498 calcium polycarbophil Drugs 0.000 claims description 4
- 239000007894 caplet Substances 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 239000003431 cross linking reagent Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 239000002662 enteric coated tablet Substances 0.000 claims description 2
- 229920001002 functional polymer Polymers 0.000 claims description 2
- 230000036571 hydration Effects 0.000 claims description 2
- 238000006703 hydration reaction Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229920000570 polyether Polymers 0.000 claims description 2
- 230000008961 swelling Effects 0.000 claims description 2
- 206010028813 Nausea Diseases 0.000 description 8
- 230000008693 nausea Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 229960005183 paroxetine hydrochloride Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000002271 trichotillomania Diseases 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polyurethanes Or Polyureas (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9514842.5A GB9514842D0 (en) | 1995-07-20 | 1995-07-20 | Novel formulation |
| PCT/EP1996/003252 WO1997003670A1 (en) | 1995-07-20 | 1996-07-19 | Paroxetine controlled release compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO980240D0 NO980240D0 (no) | 1998-01-19 |
| NO980240L NO980240L (no) | 1998-01-20 |
| NO315637B1 true NO315637B1 (no) | 2003-10-06 |
Family
ID=10777960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19980240A NO315637B1 (no) | 1995-07-20 | 1998-01-19 | Blanding i oral doseringsform inneholdende paroxetin eller et farmasöytiskakseptabelt salt derav, samt anvendelse av og fremgangsmåte forfremstilling avblandingen |
Country Status (41)
| Country | Link |
|---|---|
| EP (2) | EP1382337A1 (pl) |
| JP (2) | JP3922392B2 (pl) |
| KR (1) | KR100468351B1 (pl) |
| CN (2) | CN1117567C (pl) |
| AP (1) | AP1052A (pl) |
| AR (1) | AR003463A1 (pl) |
| AT (1) | ATE253361T1 (pl) |
| AU (1) | AU6659196A (pl) |
| BG (1) | BG64076B1 (pl) |
| BR (1) | BR9609857A (pl) |
| CA (2) | CA2227298C (pl) |
| CY (1) | CY2408B1 (pl) |
| CZ (1) | CZ294110B6 (pl) |
| DE (1) | DE69630603T3 (pl) |
| DK (1) | DK0839039T4 (pl) |
| DZ (1) | DZ2074A1 (pl) |
| EA (2) | EA003775B1 (pl) |
| EG (1) | EG23934A (pl) |
| ES (1) | ES2208757T5 (pl) |
| GB (1) | GB9514842D0 (pl) |
| HK (1) | HK1010494A1 (pl) |
| HU (1) | HU228853B1 (pl) |
| IL (1) | IL122940A0 (pl) |
| MA (1) | MA23942A1 (pl) |
| MX (1) | MX9800571A (pl) |
| MY (1) | MY141373A (pl) |
| NO (1) | NO315637B1 (pl) |
| NZ (1) | NZ315006A (pl) |
| OA (1) | OA10652A (pl) |
| PE (1) | PE16098A1 (pl) |
| PL (1) | PL184987B1 (pl) |
| PT (1) | PT839039E (pl) |
| RO (1) | RO119119B1 (pl) |
| SI (1) | SI0839039T2 (pl) |
| SK (1) | SK284117B6 (pl) |
| TR (1) | TR199800077T1 (pl) |
| TW (1) | TW464513B (pl) |
| UA (1) | UA68328C2 (pl) |
| UY (3) | UY24288A1 (pl) |
| WO (1) | WO1997003670A1 (pl) |
| ZA (1) | ZA966148B (pl) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6638948B1 (en) | 1996-09-09 | 2003-10-28 | Pentech Pharmaceuticals, Inc. | Amorphous paroxetine composition |
| US5910319A (en) * | 1997-05-29 | 1999-06-08 | Eli Lilly And Company | Fluoxetine enteric pellets and methods for their preparation and use |
| EP1078925A1 (en) | 1997-06-10 | 2001-02-28 | Synthon B.V. | 4-Phenylpiperidine compounds |
| US5955475A (en) * | 1997-06-30 | 1999-09-21 | Endo Pharmaceuticals Inc. | Process for manufacturing paroxetine solid dispersions |
| WO1999001121A1 (en) | 1997-07-01 | 1999-01-14 | Pfizer Inc. | Sertraline salts and sustained-release dosage forms of sertraline |
| GB9808479D0 (en) * | 1998-04-22 | 1998-06-17 | Smithkline Beecham Plc | Method of treatment |
| CH689805A8 (fr) * | 1998-07-02 | 2000-02-29 | Smithkline Beecham Plc | Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant. |
| US6139875A (en) * | 1998-09-29 | 2000-10-31 | Eastman Chemical Company | Aqueous enteric coating composition and low gastric permeability enteric coating |
| EP1161241B1 (de) | 1999-03-12 | 2005-12-07 | Aesica Pharmaceuticals Ltd. | Stabile pharmazeutische anwendungsform für paroxetin-anhydrat |
| IE990406A1 (en) | 1999-05-20 | 2000-12-27 | Elan Corp Plc | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations. |
| DE60035579T2 (de) * | 1999-05-20 | 2008-04-17 | Elan Corp. Plc | Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme |
| WO2000078290A2 (en) * | 1999-06-22 | 2000-12-28 | Smithkline Beecham P.L.C. | Pharmaceutical composition comprising a salt of paroxetine |
| ES2159260B1 (es) * | 1999-06-22 | 2002-05-01 | Smithkline Beechan Plc | Nueva composicion de metanosulfonato de paroxetina |
| ES2162560B1 (es) * | 1999-06-25 | 2002-07-16 | Rodriguez Concepcion Pena | Uso de fluoxetina, paroxetina y otros isrs para la fabricacion de medicamentos con el fin de aumentar la capacidad de abstenerse de substancias o actividades que crean dependencia. |
| AR030557A1 (es) | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
| US6482440B2 (en) * | 2000-09-21 | 2002-11-19 | Phase 2 Discovery, Inc. | Long acting antidepressant microparticles |
| CA2457385A1 (en) * | 2001-08-06 | 2003-02-20 | Dr. Reddy's Laboratories Ltd. | Improved enteric formulation of fluoxetin |
| GB2392385A (en) * | 2002-09-02 | 2004-03-03 | Cipla Ltd | Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone |
| TW200517106A (en) | 2003-10-29 | 2005-06-01 | Wyeth Corp | Sustained release pharmaceutical compositions |
| EP1734920A2 (en) * | 2004-02-13 | 2006-12-27 | Neuromolecular Inc. | Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
| WO2005107716A1 (en) * | 2004-03-25 | 2005-11-17 | Cadila Healthcare Limited | Controlled release paroxetine-containing tablets based on a core and a coating |
| AU2006274565B2 (en) * | 2005-08-02 | 2012-05-17 | Lupin Limited | Novel controlled release compositions of selective serotonin reuptake inhibitors |
| KR100591142B1 (ko) * | 2005-11-04 | 2006-06-20 | 지엘팜텍 주식회사 | 파록세틴을 활성물질로 함유하는 장용성 서방형 정제 |
| US20090130206A1 (en) * | 2006-05-09 | 2009-05-21 | Umesh Nandkumar Khatavkar | Controlled Release Compositions of an Antidepressant Agent |
| KR100885029B1 (ko) | 2007-02-07 | 2009-02-23 | 지엘팜텍 주식회사 | 경구투여용 서방성 삼중정제 |
| WO2009006299A2 (en) * | 2007-06-29 | 2009-01-08 | Dr. Reddy's Laboratories Ltd. | Multi-particulate systems |
| US8822498B2 (en) | 2007-09-13 | 2014-09-02 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof |
| TW201010743A (en) | 2008-09-05 | 2010-03-16 | Otsuka Pharma Co Ltd | Pharmaceutical solid preparation |
| PL2470166T3 (pl) * | 2009-08-24 | 2013-11-29 | H Lundbeck As | Nowe kompozycje 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny |
| CN103371982A (zh) * | 2012-04-20 | 2013-10-30 | 王进京 | 盐酸帕罗西汀肠溶控释片新型处方组成及制备方法 |
| JP2015522047A (ja) * | 2012-07-09 | 2015-08-03 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 光保護パーソナルケア組成物 |
| CN103550182B (zh) * | 2013-10-29 | 2015-04-08 | 吉林省东盟制药有限公司 | 一种肠溶缓释组合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8626936D0 (en) * | 1986-11-11 | 1986-12-10 | Ferrosan As | Treatment |
| MC2025A1 (fr) * | 1988-04-20 | 1990-04-25 | Asta Pharma Ag | Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee |
| IT1237904B (it) * | 1989-12-14 | 1993-06-18 | Ubaldo Conte | Compresse a rilascio a velocita' controllata delle sostanze attive |
| JPH0436237A (ja) * | 1990-06-01 | 1992-02-06 | Taiho Yakuhin Kogyo Kk | 抗腫瘍性複合製剤 |
| DK0497956T3 (da) * | 1990-08-21 | 1996-08-12 | Theratech Inc | Præparater med reguleret frigivelse |
| CA2096853A1 (en) * | 1990-11-24 | 1992-05-25 | Anthony Michael Johnson | Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia |
| AU657973B2 (en) * | 1991-05-07 | 1995-03-30 | Dynagen, Inc. | A controlled, sustained release delivery system for smoking cessation |
| JPH05139964A (ja) * | 1991-11-14 | 1993-06-08 | Takada Seiyaku Kk | 塩酸メキシレチン腸溶性製剤 |
| EP0654263B1 (en) * | 1993-11-23 | 2002-01-23 | Euro-Celtique S.A. | Method for preparing a sustained release composition |
| IT1274241B (it) * | 1993-12-03 | 1997-07-15 | Smithkline Beecham Farma | Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono |
| CA2143070C (en) * | 1994-02-22 | 2001-12-18 | Pankaj Modi | Oral controlled release liquid suspension pharmaceutical formulation |
| GB9422154D0 (en) * | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
| CA2216934A1 (en) * | 1995-04-03 | 1996-10-10 | Abbott Laboratories | Homogeneous mixtures of low temperature-melting drugs and additives for controlled release |
-
1995
- 1995-07-20 GB GBGB9514842.5A patent/GB9514842D0/en active Pending
-
1996
- 1996-07-17 DZ DZ960118A patent/DZ2074A1/fr active
- 1996-07-18 EG EG68296A patent/EG23934A/xx active
- 1996-07-18 MA MA24317A patent/MA23942A1/fr unknown
- 1996-07-18 AR ARP960103639A patent/AR003463A1/es not_active Application Discontinuation
- 1996-07-18 MY MYPI96002956A patent/MY141373A/en unknown
- 1996-07-19 ZA ZA9606148A patent/ZA966148B/xx unknown
- 1996-07-19 EP EP03078259A patent/EP1382337A1/en not_active Withdrawn
- 1996-07-19 CA CA002227298A patent/CA2227298C/en not_active Expired - Lifetime
- 1996-07-19 IL IL12294096A patent/IL122940A0/xx not_active IP Right Cessation
- 1996-07-19 CA CA002445678A patent/CA2445678C/en not_active Expired - Lifetime
- 1996-07-19 DE DE69630603T patent/DE69630603T3/de not_active Expired - Lifetime
- 1996-07-19 MX MX9800571A patent/MX9800571A/es active IP Right Grant
- 1996-07-19 EA EA199800140A patent/EA003775B1/ru not_active IP Right Cessation
- 1996-07-19 AT AT96926388T patent/ATE253361T1/de active
- 1996-07-19 TW TW085108758A patent/TW464513B/zh not_active IP Right Cessation
- 1996-07-19 EP EP96926388A patent/EP0839039B2/en not_active Expired - Lifetime
- 1996-07-19 PE PE1996000548A patent/PE16098A1/es not_active IP Right Cessation
- 1996-07-19 UY UY24288A patent/UY24288A1/es not_active IP Right Cessation
- 1996-07-19 EA EA200100022A patent/EA003508B1/ru not_active IP Right Cessation
- 1996-07-19 BR BR9609857A patent/BR9609857A/pt not_active Application Discontinuation
- 1996-07-19 PT PT96926388T patent/PT839039E/pt unknown
- 1996-07-19 KR KR10-1998-0700380A patent/KR100468351B1/ko not_active IP Right Cessation
- 1996-07-19 TR TR1998/00077T patent/TR199800077T1/xx unknown
- 1996-07-19 CN CN96196819A patent/CN1117567C/zh not_active Expired - Lifetime
- 1996-07-19 HU HU9900299A patent/HU228853B1/hu unknown
- 1996-07-19 JP JP50632597A patent/JP3922392B2/ja not_active Expired - Lifetime
- 1996-07-19 ES ES96926388T patent/ES2208757T5/es not_active Expired - Lifetime
- 1996-07-19 UA UA98010283A patent/UA68328C2/uk unknown
- 1996-07-19 CN CNB031490468A patent/CN1282456C/zh not_active Expired - Lifetime
- 1996-07-19 PL PL96324553A patent/PL184987B1/pl unknown
- 1996-07-19 SI SI9630661T patent/SI0839039T2/sl unknown
- 1996-07-19 NZ NZ315006A patent/NZ315006A/xx not_active IP Right Cessation
- 1996-07-19 WO PCT/EP1996/003252 patent/WO1997003670A1/en active IP Right Grant
- 1996-07-19 AU AU66591/96A patent/AU6659196A/en not_active Abandoned
- 1996-07-19 AP APAP/P/1998/001177A patent/AP1052A/en active
- 1996-07-19 RO RO98-00082A patent/RO119119B1/ro unknown
- 1996-07-19 SK SK53-98A patent/SK284117B6/sk not_active IP Right Cessation
- 1996-07-19 CZ CZ1998183A patent/CZ294110B6/cs not_active IP Right Cessation
- 1996-07-19 DK DK96926388T patent/DK0839039T4/da active
-
1997
- 1997-01-10 UY UY24436A patent/UY24436A1/es not_active IP Right Cessation
-
1998
- 1998-01-19 NO NO19980240A patent/NO315637B1/no not_active IP Right Cessation
- 1998-01-20 OA OA9800005A patent/OA10652A/en unknown
- 1998-02-17 BG BG102259A patent/BG64076B1/bg unknown
- 1998-11-06 HK HK98111807A patent/HK1010494A1/xx not_active IP Right Cessation
-
2000
- 2000-07-13 UY UY26242A patent/UY26242A1/es not_active Application Discontinuation
-
2004
- 2004-03-15 CY CY0400019A patent/CY2408B1/xx unknown
-
2006
- 2006-04-27 JP JP2006123731A patent/JP2006265258A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO315637B1 (no) | Blanding i oral doseringsform inneholdende paroxetin eller et farmasöytiskakseptabelt salt derav, samt anvendelse av og fremgangsmåte forfremstilling avblandingen | |
| US6548084B2 (en) | Controlled release compositions | |
| CA2653955C (en) | Pharmaceutical compositions for sustained release of phenylephrine | |
| Majeed et al. | Formulation and evaluation of bilayer matrix tablets of amoxicillin and esomeprazole as an oral modified release dosage form for treatment of peptic ulcer | |
| US6300343B1 (en) | Method of treatment | |
| AU2006274565A1 (en) | Novel controlled release compositions of selective serotonin reuptake inhibitors | |
| AU748804B2 (en) | Paroxetine controlled release compositions | |
| KR20010021644A (ko) | 신규한 조성물 | |
| Dementia et al. | TOTAL 100.0 | |
| SA96170336B1 (ar) | تراكيب مضبوطة الاطلاق controlled release |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |